The iNSiGHT DXA system is a cutting-edge in vivo Dual Energy X-Ray Absorptiometry (DXA/DEXA) technology intended for preclinical studies. It offers a comprehensive solution for assessing a wide range ...
12d
FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials
FDA has qualified the first surrogate endpoint for bone fractures in anti-osteoporosis drug trials for at-risk ...
The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback